Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 206210, held by Actavis Labs Fl. Topiramate.
As of Nov 15, 2026, ANDA 206210 (Topiramate), held by Actavis Labs Fl, was first approved by FDA on Mar 10, 2023, with 3 approved supplements and 0 published complete response letters.
Topiramate extended-release capsules are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older; adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome (LGS) in patients 6 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate extended-release capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older. 1.
| Mar 10, 2023 | Original application | Approved | None posted |
| Mar 10, 2023 | Original application | Approved |
| Topiramate25MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate50MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate100MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate200MG · capsule, extended release;oral | Topiramate | Rx |
| Oct 15, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 23, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 23, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 10, 2023 | Original application | Approved | None posted |
| Mar 10, 2023 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters